Home > Newsletters > FDAnews Drug Daily Bulletin > J&J Settles Risperdal-Related Consumer Fraud Claims With 36 States, DC for $181 Million
FDAnews Drug Daily Bulletin
Sept. 4, 2012 | Vol. 9 No. 173
J&J Settles Risperdal-Related Consumer Fraud Claims With 36 States, DC for $181 Million
Johnson & Johnson (J&J) has agreed to pay $181 million and enter into a consent decree with 36 states and the District of Columbia to settle allegations that its Janssen subsidiary marketed prescription antipsychotic Risperdal off-label in violation of consumer protection laws, J&J says. The multi-state settlement is not an admission of wrongdoing or breach of law and was entered into to avoid unnecessary expense and a prolonged legal process, J&J said Aug. 30. As part of the deal, J&J promised not to promote Risperdal (risperidone) or any of its atypical antipsychotics for off-label uses or make any false or misleading claims related to those products.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.